Last $5.06 USD
Change Today -0.15 / -2.88%
Volume 757.6K
NWBO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

northwest biotherapeutics (NWBO) Snapshot

Open
$5.22
Previous Close
$5.21
Day High
$5.35
Day Low
$4.91
52 Week High
03/11/14 - $10.64
52 Week Low
12/19/13 - $3.20
Market Cap
314.8M
Average Volume 10 Days
521.7K
EPS TTM
$-1.08
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NORTHWEST BIOTHERAPEUTICS (NWBO)

Related News

No related news articles were found.

northwest biotherapeutics (NWBO) Related Businessweek News

No Related Businessweek News Found

northwest biotherapeutics (NWBO) Details

Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

9 Employees
Last Reported Date: 04/1/14
Founded in 1996

northwest biotherapeutics (NWBO) Top Compensated Officers

Chairperson, Chief Executive Officer, Preside...
Total Annual Compensation: $360.0K
Founder, Chief Scientific Officer, Secretary ...
Total Annual Compensation: $295.7K
Senior Vice President of Clinical Research
Total Annual Compensation: $300.0K
Chief Technical Officer
Total Annual Compensation: $325.2K
Senior Vice President of Business Development
Total Annual Compensation: $348.0K
Compensation as of Fiscal Year 2013.

northwest biotherapeutics (NWBO) Key Developments

Northwest Biotherapeutics, Inc. announced delayed 10-Q filing

On 11/14/2014, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

UK Authorities Designates Northwest Biotherapeutics' Cancer Vaccine as a Promising Innovative Medicine

Northwest Biotherapeutics announced that its DCVax-L is the first product to receive formal designation as a "Promising Innovative Medicine" (PIM) under the new "Early Access to Medicines Scheme" (EAMS) launched in the UK in April 2014. A PIM is the first step in a 2-step process for early access approval under the EAMS. The PIM designation for DCVax-L covers all malignant gliomas, which would include both Glioblastoma multiforme (the most severe grade) as well as less malignant grades, and would include both newly diagnosed and recurrent gliomas.

Northwest Biotherapeutics, Inc. announced delayed 10-Q filing

On 08/14/2014, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWBO:US $5.06 USD -0.15

NWBO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWBO.
View Industry Companies
 

Industry Analysis

NWBO

Industry Average

Valuation NWBO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 526.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 509.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORTHWEST BIOTHERAPEUTICS, please visit www.nwbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.